| 引用本文:张兰会，赵参军，吴昊，党媛媛，郑瑾.升阳益胃汤加减在晚期胃癌阳虚湿阻证化疗患者中的作用[J].世界中医药,2020,(24):. |
|
| 升阳益胃汤加减在晚期胃癌阳虚湿阻证化疗患者中的作用 |
| Exploration on the Effect of Shengyang Yiwei Decoction Plus Reduction in Chemotherapy for Advanced Gastric Cancer Patients with Wet Resistance Syndrome of Yang Deficiency |
| 投稿时间：2020-05-29 |
| DOI：10.3969/j.issn.1673-7202.2020.24.012 |
| 中文关键词: 升阳益胃汤 胃癌 阳虚湿阻证 化疗 效果 |
| English Keywords:Shengyang Yiwei Decoction Gastric cancer Wet resistance syndrome of yang deficiency Chemotherapy Effect |
| 基金项目:国家自然科学基金面上项目（30271626） |
|
| 摘要点击次数: 331 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨升阳益胃汤加减对晚期胃癌阳虚湿阻证化疗患者的作用。方法：选取2017年10月至2019年8月中国人民解放军空军军医大学唐都医院收治的晚期胃癌阳虚湿阻证化疗患者86例作为研究对象，采用随机数表法分为对照组（常规化疗）和观察组（常规化疗＋升阳益胃汤加减），每组43例。比较2组患者治疗前后的中医积分及抗肿瘤疗效，肿瘤标志物水平，T淋巴细胞亚群水平及不良反应发生率。结果：2组治疗后主症积分、次症积分、总积分均降低（P<0.05），观察组主症积分、次症积分、总积分均低于对照组（P<0.05）；2组抗肿瘤疗效分布差异有统计学意义（P<0.05），观察组有效率高于对照组（P<0.05）；2组治疗后糖类抗原125（CA125）、糖类抗原19-9（CA19-9）、癌胚抗原（CEA）、细胞角蛋白19片段抗原21-1（CY-FRA21-1）水平均降低（P<0.05），观察组CA125、CA19-9、CEA、CY-FRA21-1水平均低于对照组（P<0.05）；2组治疗后CD3+、CD4+、CD4+/CD8+水平均提高（P<0.05），观察组CD3+、CD4+、CD4+/CD8+水平均高于对照组（P<0.05）；2组恶心呕吐、脱发、贫血、血小板减少发生率比较，差异无统计学意义（P>0.05）。结论：对晚期胃癌阳虚湿阻证化疗患者实施升阳益胃汤加减治疗可显著减轻患者病情，增强抗肿瘤疗效，降低肿瘤标志物水平，提高机体T淋巴细胞免疫功能且安全性良好。 |
| English Summary: |
| To investigate the effect of Shengyang Yiwei Decoction on the chemotherapy in advanced gastric cancer patients with wet resistance syndrome of yang deficiency.Methods:A total of 86 patients with chemotherapy for advanced gastric and wet resistance syndrome of yang deficiency admitted to Tangdu Hospital,Air Force Medical University from October 2017 to August 2019 were selected and randomly divided into the conventional group(43 patients,conventional chemotherapy)and the study group(43 patients,conventional chemotherapy＋Shengyang Yiwei Decoction plus or minus).The traditional Chinese medicine score,antitumor efficacy,the levels of tumor markers,T lymphocyte subsets before and after treatment were compared between the 2 groups.The occurrence of adverse reactions in the 2 groups was compared.Results:After treatment,the main symptom score,secondary symptom score and total score of the 2 groups were all reduced(P<0.05).The main score,secondary score and total score of the study group were all lower than those of the conventional group(P<0.05).The distribution of anti-tumor efficacy was significantly different between the 2 groups(P<0.05),and the effective rate of the study group was higher than that of the conventional group(P<0.05).The levels of saccharide antigen 125(CA125),saccharide antigen 19-9(CA19-9),oncoembryonic antigen(CEA)and cytokeratin 19 fragment antigen 21-1(CY-FRA21-1)were all reduced after treatment in the 2 groups(P<0.05).The levels of CA125,CA19-9,CEA and CY-FRA21-1 in the study group were all lower than those in the conventional group(P<0.05).The levels of CD3+,CD4+ and CD4+/CD8+ in the 2 groups increased after treatment(P<0.05),and the levels of CD3+,CD4+ and CD4+/CD8+ in the study group were all higher than those in the conventional group(P<0.05).There was no significant difference in the incidence of nausea,vomiting,hair loss,anemia and thrombocytopenia between the 2 groups(P> 0.05).Conclusion:For thechemotherapy for advanced gastric cancerpatients with wet resistance syndrome of yang deficiency,the treatment of Shengyang Yiwei Decoction can significantly reduce the patient's condition,enhance the anti-tumor efficacy,reduce the level of tumor markers,improve the immune function of T cells and good safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
